CyBorD or VCd or cybord is given to alleviate symptoms and slow the progression of multiple myeloma, not for disease cure. After treatment, patients who respond to CyBorD are typically …

May 10, 2012 · Cyclophosphamide, bortezomib, and dexamethasone (CyBorD) is highly effective in multiple myeloma. We treated patients with light chain amyloidosis (AL) before stem cell …

We have studied a three drug combination with bortezomib, cyclophosphamide and dexamethasone (CyBorD) on a 28 day cycle in the treatment of newly diagnosed multiple …

Reeder CB, Reece DE, Kukreti V, et al. Onc e- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010; 115(16): 3416-7.

Ensure supply chain security and product reliability with Cybord’s AI-driven component inspection. Achieve real-time traceability & compliance.

May 20, 2014 · CYBORD has been validated as an upfront strategy with excellent long-term outcomes, but its use in relapsed disease has not been fully reported. We report a series of 55 …

Background: CyBorD (cyclophosphamide, bortezomib, and dexamethasone) is an effective regimen for the treatment of patients with newly diagnosed immunoglobulin light chain (AL) …

Jan 19, 2015 · Cyclophosphamide, bortezomib and dexamethasone (CyBorD) is a highly active three-drug induction regimen for untreated transplant-eligible multiple myeloma patients.

Dec 6, 2014 · Combinations of novel drugs have improved and deepened response and this is true for CyBORD, a regimen able to induce rapid and deep responses. Based on the above …

Nov 29, 2018 · Conclusions: CyBorD-DARA is a highly active, well tolerated induction therapy for NDMM patients undergoing ASCT. These data support the further development of this …